Announcements
- Addex Provides Corporate Update and Financial Guidance
- Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
- Addex Reports Q3 2022 Financial Results and Provides Corporate Update
- Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
- Addex Increases Issued Share Capital to Create Treasury Shares
- Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
- Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
More ▼
Key statistics
On Friday, Addex Therapeutics Ltd (ADXN:NAQ) closed at 1.44, 161.82% above the 52 week low of 0.55 set on Dec 22, 2022.
52-week range
Markit short selling activity
Open | 1.26 |
---|---|
High | 1.68 |
Low | 1.26 |
Bid | 1.30 |
Offer | 1.40 |
Previous close | 1.25 |
Average volume | 375.04k |
---|---|
Shares outstanding | 19.22m |
Free float | 18.23m |
P/E (TTM) | -- |
Market cap | 25.90m USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Feb 03 2023 21:00 GMT.
More ▼